FDA Approves ABRAXANE for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer

Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and DrugAdministration (FDA) has approved ABRAXANE^® (paclitaxel protein-boundparticles for injectable suspension) (albumin-bound) for the first-linetreatment of locally advanced or metastatic non-small cell lung cancer, incombination with carboplatin, in patients who are not candidates for curativesurgery or radiation therapy.“Non-small cell is the most common type of lung cancer, the leading cause ofcancer death in the United States,” said Dr. Mark A. Socinski, MD, Director,Lung Cancer Section, Division of Hematology/Oncology, University ofPittsburgh, and lead investigator of ABRAXANE phase II and phase III lungcancer trials. “The FDA approval of ABRAXANE is exciting for healthcareprofessionals because it offers an important new treatment option for alltypes of non-small cell lung cancer patients, in an area that has seen fewtreatment advancements in recent years.”